As the diagnostic landscape evolves, several patterns are emerging across both clinical research and market innovation.

Detailed price information for Biomark Diagnostics Inc (BUX-CN) from The Globe and Mail including charting and trades.

Expanding U.S. market access with an experienced technology investor and AI-driven growth strategistVancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: ...

LiverTrace is designed for adults considered at risk for liver cancer, including those with previous liver conditions.

A new AI tool BMVision speeds up kidney cancer detection, cutting radiology review time by a third and supporting earlier, ...

VANCOUVER, BC, Dec. 31, 2025 /CNW/ -- The precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035([1]) , driven by a fundamental shift in cancer ...

A blood-based liquid biopsy test detects early-onset colorectal cancer with strong diagnostic performance and high ...

Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: ...

OHSU radiation oncologist presents promising study findings, launches a third, Medicare-backed study Nima Nabavizadeh, M.D., ...

Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of ...

Cancer has long been treated as a mass of rogue cells, but the real power lies in the intricate communication networks ...